![Direct Oral Anticoagulants and Coronary Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology Direct Oral Anticoagulants and Coronary Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/b9b03307-101a-4db7-8041-41d17281d888/atvbaha.121.317171.fig01.jpg)
Direct Oral Anticoagulants and Coronary Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology
![GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC](https://www.ivasc.eu/wp-content/uploads/2017/04/Diapositive2.png)
GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC
![PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.](https://d3i71xaburhd42.cloudfront.net/ff59b80543e524a4f3127f4ee15bd1a2ecf85738/3-TableII-1.png)
PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
![Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/e33c355b-f2db-41d6-9f66-65babb0f0bd1/gr2_lrg.jpg)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
![PDF) A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study PDF) A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study](https://i1.rgstatic.net/publication/291185918_A_Randomized_Trial_to_Compare_the_Safety_of_Rivaroxaban_versus_Aspirin_in_Addition_to_Either_Clopidogrel_or_Ticagrelor_in_Acute_Coronary_Syndrome_The_Design_of_the_GEMINI-ACS-1_Phase_II_Study/links/5e6ffd9392851c1a689a5e17/largepreview.png)
PDF) A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
![PDF) A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study PDF) A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study](https://www.researchgate.net/publication/291185918/figure/fig1/AS:869847223267328@1584399147312/figure-fig1_Q320.jpg)
PDF) A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
![Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/f1206957-1af8-40dc-bad5-6ea784459ee2/gr1_lrg.gif)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
Sanne van W💉ssen on Twitter: "Gemini-ACS1 results. Rivaroxaban shows same rate of clinically relevant bleeding compared to aspirin #ACS #ACC17 https://t.co/hZZHSHkVAB" / Twitter
![Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/11b5aaee-075d-4059-98b4-8e0a1ecd7587/gr3.gif)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
![GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC](https://www.ivasc.eu/wp-content/uploads/2017/04/Diapositive1.png)
GEMINI-ACS-1, une étude d'envergure pour évaluer de nouvelles combinaisons de traitements anti-plaquettaires - IVASC
![Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology](https://challengesincardiology.com/wp-content/uploads/2017/04/Diapositivo25.jpg)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology
![Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology](https://challengesincardiology.com/wp-content/uploads/2017/04/Diapositivo22.jpg)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial | Challenges in Cardiology
![PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.](https://d3i71xaburhd42.cloudfront.net/ff59b80543e524a4f3127f4ee15bd1a2ecf85738/2-TableI-1.png)
PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
![A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study - ScienceDirect A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002870316000156-gr2.jpg)
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study - ScienceDirect
![Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2095457388/2077627720/gr1.gif)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
![A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus. - ppt download A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus. - ppt download](https://slideplayer.com/slide/12919298/78/images/5/Inclusion+Criteria+Randomization+within+10+days+of+an+ACS+event.jpg)
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus. - ppt download
![PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. PDF] A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.](https://d3i71xaburhd42.cloudfront.net/ff59b80543e524a4f3127f4ee15bd1a2ecf85738/3-Figure1-1.png)